Abstract 142P
Background
Liquid biopsy is an emerging technology capable of detecting cancer, while CT-imaging is the gold standard. We aim to correlate imaging features from CT-scans to liquid biopsy ctDNA tumor fraction (TF) and blood Tumor Mutational Burden (bTMB).
Methods
This retrospective multicentric study included 1017 patients with metastatic cancer who underwent a variety of treatments. Liquid biopsy and contemporaneous CT-scans were collected. TF and bTMB values were computed using FoundationOne Liquid CDX solution by Roche, with high tumor fraction being over 10%. Two expert radiologists outlined all cancerous lesions in the largest axial diameter. Total tumor volume (TTV) was defined as the sum of estimated lesion volumes. Training set consisted of data from several imaging centers, while the validation set was single-center. Continuous value distributions by category were tested using the Mann-Whitney U-test, and a threshold was set with ROC curve analysis using Youden's Index. This cutoff defined high and low groups, and a Χ2 test of independence was used to examine the correlation. Sensitivity and specificity were reported with imaging features taken as the gold standard. Subanalyses were run on patients with liver lesions.
Results
Overall, 55294 lesions were annotated, most commonly located in the lung (n=20074), liver (n=11297) and lymph nodes (n=10222). The train and validation sets included 599 and 418 patients. Preliminary analyses were performed on the train set. Patients with low TF had significantly less TTV than those with high TF (p<0.001). ROC analysis yielded an AUC of 0.63 with a threshold of 106 cm3. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 76% and 42%. For patients with liver lesions (n=253) , TTV threshold was 108 cm3 with an AUC of 0.66. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 82% and 42%.
Conclusions
Analysis showed significant correlation between TTV and ctDNA TF. Sensitivity was higher for patients with liver lesions, suggesting that some organs shed tumoral DNA more than others. The study of tumor heterogeneity on imaging and its correlation to bTMB is in progress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Clinical and molecular features of PTCH1 mutant in solid tumors
Presenter: Xuezheng Li
Session: Poster session 01
218P - Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Presenter: WON SUK LEE
Session: Poster session 01
219P - Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Presenter: Eloisa Jantus Lewintre
Session: Poster session 01
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01
221P - Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
Presenter: Chan Kim
Session: Poster session 01
222P - Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
Presenter: Natalie Cook
Session: Poster session 01
223P - Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Presenter: Gianluca Mauri
Session: Poster session 01
224P - Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Presenter: Afaf Abed
Session: Poster session 01
225P - Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country
Presenter: Milton Lombana Quinonez
Session: Poster session 01
226P - LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Presenter: Jiangfeng Ye
Session: Poster session 01